Opening Asia for Russia

China approves recombinant vaccine

27.02.2021 123 просмотров

On February 25, the National Medicines Administration of China (NMPA) approved the application for registration of a domestically produced recombinant COVID-19 vaccine with certain conditions.

The vaccine was developed jointly by the PLA Academy of Military Sciences Research Group and the Chinese biopharmaceutical company CanSino Biologics Inc.

China New Vaccine 3.jpg

a recombinant coronavirus vaccine with a modified defective adenovirus as a vector. This drug was the first adenoviral vector-based COVID-19 vaccine to be approved for use in China.

China New Vaccine 4.jpg

According to NMPA regulations, the Chen Wei team must continue its research work, complete conditional approval requirements, and provide follow-up study results in a timely manner.

China New Vaccine 5.jpg

“Among all vaccines approved for market launch in the country, our drug is the only one that needs to be injected only once. With a single vaccination in the human body, both cellular and humoral immunity will be activated. Effective immune protection will be developed after 14 days. In addition, this vaccine can be transported and stored at a temperature of two to eight degrees above zero Celsius,” said Hou Lihua, a researcher at the Military Medical Research Institute of the PLA Academy of Military Sciences.

China New Vaccine 6.jpg

March 16th 2020, Chinese scientists began the first phase of clinical trials of this vaccine in Wuhan (Hubei Province, Central China). At that time, this drug became the first vaccine candidate in the world to enter the stage of clinical trials.

On February 8, 2021, an interim analysis of data from the third phase of clinical trials of this vaccine was completed.

< img width="800" alt="China New Vaccine 7.jpg" src="/upload/medialibrary/35d/35d222686755401a1a01b281492fe097.jpg" height="426" title="China New Vaccine 7.jpg">
< br> In Phase 3 clinical trials conducted in Pakistan, researchers found that 28 days after vaccine administration, 100% efficacy in preventing severe forms of COVID-19 disease was achieved, with an overall protective effect of 74.8%.
The drug has already received emergency use approval in Pakistan and Mexico.

China New Vaccine 2.jpg

Chen Wei truly believes that the vaccine they created It will help not only China, but the whole world in containing the spread of COVID-19.

“I want to thank every volunteer and the competent departments who have worked with us around the clock and provided us with significant support in the development of a vaccine. The fight against the epidemic is another test for our team. We hope that China's scientific and technological innovation will make an even greater contribution to the global efforts to prevent and control the coronavirus,” she said.

Новости партнёров